Grant: Catalyst Grant - Mild Traumatic Brain Injury - Blast-Induced
University of British Columbia
$0.00
Investigation into the molecular mechanisms of AMPAR trafficking following primary blast-induced mTBI
FY 2012-13
Summary
In recent years, the increasing use of improvised explosive devices during the conflicts in Afghanistan and Iraq has resulted in an increase in mild-to-moderate traumatic brain injuries (mTBI) suffered by soldiers in combat areas. However, due to the complex nature of the injuries, treatment options are limited. Often soldiers exposed to minor blasts event, who initially exhibit no outward negative effects, sometimes develop memory and behavior changes days or months after the initial event. For these reasons, mTBI has become a major focus of casualty care. Our objectives are to achieve a better understanding of the biological mechanisms by which mTBI produces pathological changes to the brain, in order to drive the development of novel pharmacotherapies. Previous studies have revealed that one consequence of a traumatic blast injury is the abnormal release of an excitatory signaling molecule (glutamate) in the brain. This abnormal release can result in overstimulation of glutamate's normal receptors (known as excitotoxicty), and this can lead to the death and dysfunction of brain cells. We have previously developed a novel drug (GluR2-3Y) which has shown an ability to block the excitotoxic overstimulation of glutamate receptors in a cellular model of stroke, thereby reducing the death of brain cells. In our present study, we propose to study the biological changes that occur in the brain following mTBI, and test the ability of our drug to reduce the death and dysfunction of brain cells that occur following mTBI. We believe that our proposed study will provide critical information surrounding the biological changes that occur in the brain following mTBI, and if our GluR2-3Y drug shows a similar effect in mitigating the damage caused by mTBI as it does in a model of stroke, we believe that it may have the potential to drive the development of new therapeutics to treat these injuries and have a positive impact on the health of soldiers suffering from mTBI.
Department
Program
Catalyst Grant - Mild Traumatic Brain Injury - Blast-Induced
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
283395
Name
Wang Yu Tian
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Department of National Defence R&D
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Mild Traumatic Brain Injury
Projecttitle
Investigation into the molecular mechanisms of AMPAR trafficking following primary blast-induced mTBI
Programtype2
Operating Grants
Orgnameinp2
University of British Columbia
Cihramount2
$0
Cihrequipment2
$0
Programname2
Catalyst Grant - Mild Traumatic Brain Injury - Blast-Induced
Keyworddelim
Ampa Receptor; Animal Physiology; Blast Injury; Cell Biology; Endocytosis; Molecular Biology; Neurodegeneration; Receptor Trafficking; Therapeutics; Traumatic Brain Injury
Abstract
In recent years, the increasing use of improvised explosive devices during the conflicts in Afghanistan and Iraq has resulted in an increase in mild-to-moderate traumatic brain injuries (mTBI) suffered by soldiers in combat areas. However, due to the complex nature of the injuries, treatment options are limited. Often soldiers exposed to minor blasts event, who initially exhibit no outward negative effects, sometimes develop memory and behavior changes days or months after the initial event. For these reasons, mTBI has become a major focus of casualty care. Our objectives are to achieve a better understanding of the biological mechanisms by which mTBI produces pathological changes to the brain, in order to drive the development of novel pharmacotherapies. Previous studies have revealed that one consequence of a traumatic blast injury is the abnormal release of an excitatory signaling molecule (glutamate) in the brain. This abnormal release can result in overstimulation of glutamate's normal receptors (known as excitotoxicty), and this can lead to the death and dysfunction of brain cells. We have previously developed a novel drug (GluR2-3Y) which has shown an ability to block the excitotoxic overstimulation of glutamate receptors in a cellular model of stroke, thereby reducing the death of brain cells. In our present study, we propose to study the biological changes that occur in the brain following mTBI, and test the ability of our drug to reduce the death and dysfunction of brain cells that occur following mTBI. We believe that our proposed study will provide critical information surrounding the biological changes that occur in the brain following mTBI, and if our GluR2-3Y drug shows a similar effect in mitigating the damage caused by mTBI as it does in a model of stroke, we believe that it may have the potential to drive the development of new therapeutics to treat these injuries and have a positive impact on the health of soldiers suffering from mTBI.
Competitiondate
201210
Approvedterm2
1 yr 0 mth
Pinamesdelim
Wang, Yu Tian
Approvedterm
1 an 0 mois